| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.03B | +57.8% |
| Gross profit | ¥0.11B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | +15.4% |
| Gross margin | 10.6% | Net margin 1.5% |
| Revenue Q/Q | +61.4% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.92B | 89.4% |
| R&D | ¥0.04B | 3.5% |
| SG&A | ¥0.04B | 3.6% |
| Tax & other | ¥0.01B | 0.7% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
盈建科 ・ 中英科技 ・ 药易购 ・ 信测标准 ・ 秋田微 ・ 南极光 ・ 创识科技 ・ 易瑞生物 ・ 春晖智控 ・ 曼卡龙 ・ 恒而达 ・ 德必集团
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies